Gielkens H A, de Boer S Y, Lam W F, Rovati L C, Lamers C B, Masclee A A
Department of Gastroenterology-Hepatology, Leiden University Medical Center, The Netherlands.
Eur J Gastroenterol Hepatol. 1997 Dec;9(12):1227-31.
Recent studies have demonstrated that separate intravenous infusion of amino acids (IVAA) at high doses induces gallbladder emptying. However, little is known about the mechanisms mediating IVAA-induced gallbladder contraction.
To investigate whether the effect of IVAA on gallbladder motility is mediated by the cholinergic system and/or cholecystokinin (CCK), the major hormonal stimulus for gallbladder contraction. Six healthy male volunteers were studied in random order on five occasions using: (a) IVAA, (b) loxiglumide (CR 1505, a selective CCK-A receptor antagonist), (c) IVAA plus loxiglumide, (d) atropine and (e) IVAA plus atropine. Gallbladder volumes (ultrasonography) and plasma CCK levels (radioimmunoassay) were determined every 15 min for 60 min before and for 120 min during intravenous infusion of amino acids (Vamin 18EF; 250 mg protein/kg/h) and/or loxiglumide (10 mg/kg/h) and/or atropine (0.005 mg/kg/h).
IVAA significantly (P < 0.05) reduced gallbladder volume from 32 +/- 5 ml to 17 +/- 2 ml but induced only a small and transient increase in plasma CCK levels. Loxiglumide given alone significantly (P < 0.05) increased fasting gallbladder volume to 190% of the basal value. IVAA-induced gallbladder emptying was completely abolished by loxiglumide. Maximal gallbladder relaxation during IVAA plus loxiglumide was not significantly different compared to loxiglumide given alone. Concomitant administration of atropine also significantly (P < 0.05) inhibited IVAA-induced gallbladder emptying.
In healthy volunteers intravenous infusion of high doses of amino acids results in a significant gallbladder contraction, which is inhibited by CCK-A receptor blockade and by atropine.
近期研究表明,大剂量单独静脉输注氨基酸(IVAA)可促使胆囊排空。然而,关于介导IVAA诱导胆囊收缩的机制却知之甚少。
为研究IVAA对胆囊运动的影响是否由胆碱能系统和/或胆囊收缩素(CCK)介导,CCK是胆囊收缩的主要激素刺激因子。6名健康男性志愿者按随机顺序接受5次研究,使用:(a)IVAA;(b)洛西丁胺(CR 1505,一种选择性CCK - A受体拮抗剂);(c)IVAA加洛西丁胺;(d)阿托品;(e)IVAA加阿托品。在静脉输注氨基酸(凡命18EF;250mg蛋白质/千克/小时)和/或洛西丁胺(10mg/千克/小时)和/或阿托品(0.005mg/千克/小时)之前60分钟和期间120分钟,每隔15分钟测定胆囊容积(超声检查)和血浆CCK水平(放射免疫测定)。
IVAA显著(P<0.05)使胆囊容积从32±5ml减少至17±2ml,但仅引起血浆CCK水平小幅短暂升高。单独给予洛西丁胺显著(P<0.05)使空腹胆囊容积增加至基础值的190%。洛西丁胺完全消除了IVAA诱导的胆囊排空。IVAA加洛西丁胺期间的最大胆囊松弛与单独给予洛西丁胺相比无显著差异。同时给予阿托品也显著(P<0.05)抑制了IVAA诱导的胆囊排空。
在健康志愿者中,静脉输注高剂量氨基酸可导致显著的胆囊收缩,CCK - A受体阻断和阿托品可抑制这种收缩。